Efficacy and Safety of Tazarotene 0.045% Lotion in Caucasian Adults With Moderate-to-Severe Acne

被引:0
|
作者
Del Rosso, James [1 ,2 ,3 ]
Gold, Linda Stein [4 ]
Tyring, Stephen [5 ]
Zeichner, Joshua [6 ]
Callender, Valerie [7 ,8 ]
Draelos, Zoe [9 ]
Werschler, William [10 ]
Cook-Bolden, Fran [11 ]
Guenin, Eric [12 ]
机构
[1] JDR Dermatol Res Thomas Dermatol, Las Vegas, NV 89149 USA
[2] Adv Dermatol & Cosmet Surg, Maitland, FL 32751 USA
[3] Tour Univ Nevada, Henderson, NV 89014 USA
[4] Henry Ford Hosp, Detroit, MI 48202 USA
[5] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA
[6] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[7] Callender Dermatol & Cosmet Ctr, Glenn Dale, MD USA
[8] Howard Univ, Coll Med, Washington, DC USA
[9] Dermatol Consulting Serv PLLC, High Point, NC USA
[10] Univ Washington, Sch Med, Seattle, WA USA
[11] Weill Cornell, Dept Dermatol, New York, NY USA
[12] Ortho Dermatol, Bridgewater, NJ USA
关键词
QUALITY-OF-LIFE; TOPICAL RETINOIDS; DOUBLE-BLIND; VULGARIS; MULTICENTER; ADAPALENE; SKIN;
D O I
暂无
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: While topical retinoids are a mainstay of acne treatment, acne can manifest differently in various skin types. The objective of these post hoc analyses from two pooled phase 3 studies was to examine efficacy and safety of tazarotene 0.045% and quality of life improvements in self-identified Caucasian adults with moderate-to-severe acne. Methods: In two phase 3, double-blind, 12-week studies (NCT03168334; NCT03168321), participants aged >= 9 years with moderateto-severe acne were randomized (1:1) to tazarotene 0.045% lotion or vehicle lotion (N=1,614); a subset of adults (>= 18 years) who selfreported Caucasian (White) race (n=645) were examined. Coprimary endpoints were inflammatory/noninflammatory lesion counts and treatment (endpoint) success (>= 2-grade reduction from baseline in Evaluator's Global Severity Score and a score of 0 [clear] or 1 [almost clear]). Quality of life, treatment-emergent adverse events (TEAEs), and cutaneous safety/tolerability were also assessed. Results: At week 12, tazarotene lotion significantly reduced lesion counts by 60% (least-squares mean percent changes from baseline, tazarotene vs vehicle: inflammatory, -61.2% vs -51.1%; noninflammatory, -59.7% vs -49.3%; P<0.001, both). Significantly more participants achieved treatment success with tazarotene lotion versus vehicle (P<0.001). Numerical improvements in qualityof-life domains were observed from baseline to week 12. Most TEAEs were unrelated to treatment, and rates of moderate-to-severe erythema decreased from baseline to week 12 with tazarotene treatment. Conclusions: Tazarotene 0.045% lotion was efficacious and well tolerated over 12 weeks and led to quality-of-life improvements in Caucasian adults with moderate-to-severe acne. These results, along with those from patients with skin of color, demonstrate that once daily tazarotene 0.045% lotion is an effective and well-tolerated treatment option regardless of race or skin color.
引用
收藏
页码:1061 / 1069
页数:9
相关论文
共 50 条
  • [21] Efficacy and safety of abrocitinib for moderate-to-severe atopic dermatitis in adolescents and adults: Meta-analysis
    Li, Ling
    Yu, Jiajun
    Chen, Baoqing
    Guo, Ying
    Yang, Yufeng
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [22] Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Assessment of Efficacy and Safety in Patients Aged 9 Years and Older
    Tyring, Stephen K.
    Kircik, Leon H.
    Pariser, David M.
    Guenin, Eric
    Bhatt, Varsha
    Pillai, Radhakrishnan
    JOURNAL OF DRUGS IN DERMATOLOGY, 2018, 17 (10) : 1084 - 1091
  • [23] Efficacy and safety of fixed-dose clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel in Hispanic participants with moderate-to-severe acne: a pooled analysis
    Callender, Valerie D.
    Baldwin, Hilary
    Gold, Linda Stein
    Cook-Bolden, Fran E.
    Guenin, Eric
    Alexis, Andrew F.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2025, 36 (01)
  • [24] Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid
    Zhang, Yihua
    Xu, Qiuyun
    Chen, Lihong
    Chen, Jiawen
    Zhang, Jing
    Zou, Ying
    Gong, Ting
    Ji, Chao
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [25] Randomized Comparison of the Safety and Efficacy of Tazarotene 0.1% Cream and Adapalene 0.3% Gel in the Treatment of Patients With at Least Moderate Facial Acne Vulgaris
    Tanghetti, Emil
    Dhawan, Sunil
    Green, Lawrence
    Del Rosso, James
    Draelos, Zoe
    Leyden, James
    Shalita, Alan
    Glaser, Dee Anna
    Grimes, Pearl
    Webster, Guy
    Barnett, Pamela
    Le Gall, Nicolas
    JOURNAL OF DRUGS IN DERMATOLOGY, 2010, 9 (05) : 549 - 558
  • [26] Novel Tretinoin 0.05% Lotion for Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in a Hispanic Population
    Cook-Bolden, Fran E.
    Weinkle, Susan H.
    Guenin, Eric
    Bhatt, Varsha
    JOURNAL OF DRUGS IN DERMATOLOGY, 2019, 18 (01) : 32 - 38
  • [27] Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in an Asian Population
    Han, George
    Armstrong, April W.
    Desai, Seemal R.
    Guenin, Eric
    JOURNAL OF DRUGS IN DERMATOLOGY, 2019, 18 (09) : 910 - 916
  • [28] Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris in a preadolescent population
    Eichenfield, Lawrence F.
    Sugarman, Jeffrey L.
    Guenin, Eric
    Harris, Susan
    Bhatt, Varsha
    PEDIATRIC DERMATOLOGY, 2019, 36 (02) : 193 - 199
  • [29] Halobetasol 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis of the Lower Extremities
    Bhatia, Neal D.
    Vlahovic, Tracey C.
    Green, Lawrence G.
    Martin, Gina
    Lin, Tina
    JOURNAL OF DRUGS IN DERMATOLOGY, 2019, 18 (10) : 1029 - 1036
  • [30] Investigating the Use of 0.3% Adapalene/2.5% Benzoyl Peroxide Gel for the Management of Moderate-to-Severe Acne in Indian Patients: A Phase 4 Study Assessing Safety and Efficacy
    Batra, Rohit
    Yogendra, M.
    Gaurkar, Sudarshan
    Mukhopadhyay, Partha
    Sen, Dyotona
    Jadhwar, Sameer
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (07)